PROCEPT BioRobotics Corporation PRCT
20.17 USD +0.73 (+3.76%)
At closeNov 3, 2026, 4:01 PM EST
20.17 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
19.00 Day range 20.33
16.67 52-week range 38.11
- YTD
- -35.89%
- 1 year
- -41.55%
Analyst view
Consensus: hold
Hold
Price target (mean) 22.25 +10.3% upside
Now 20.17
- Target (low)
- 16.00
- Target (mean)
- 22.25
- Target (high)
- 30.00
Ratings (0m) 15 5 buy · 9 hold · 1 sell
- Strong buy2
- Buy3
- Hold9
- Sell0
- Strong sell1
Recommendation trend
- This month 15
- 1 month ago 14
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.38935 | -0.42 – -0.34383 | -0.38 | -2.5% | 100.52M | +20.6% | 11 |
| Next quarter | -0.25497 | -0.29 – -0.23 | -0.53 | +51.9% | 117.81M | +54.2% | 11 |
| Current year | -1.68 | -1.82 – -1.62 | -1.72 | +2.2% | 395.29M | +28.3% | 12 |
| Next year | -1.17 | -1.53 – -0.82 | -1.68 | +30.3% | 476.25M | +20.5% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiated | — | Overweight |
| Aug 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 5, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 5, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 5, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Jul 6, 2026 | Truist Securities | Downgrade | Buy | Hold |
| Jun 24, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| Jun 11, 2026 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Apr 30, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Mar 6, 2026 | Baird | Initiated | — | Neutral |
| Mar 2, 2026 | Truist Securities | Maintained | Buy | Buy |
| Feb 26, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Feb 26, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Feb 26, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Feb 26, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 26, 2026 | B of A Securities | Downgrade | Neutral | Underperform |
| Dec 18, 2025 | Truist Securities | Maintained | Buy | Buy |
| Dec 12, 2025 | UBS | Initiated | — | Buy |
| Dec 8, 2025 | B of A Securities | Downgrade | Buy | Neutral |
| Dec 2, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 5, 2025 | TD Cowen | Maintained | Buy | Buy |
| Nov 5, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Nov 5, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 15, 2025 | Truist Securities | Maintained | Buy | Buy |
| Sep 16, 2025 | BTIG | Reiterated | Neutral | Neutral |
| Sep 2, 2025 | Oppenheimer | Upgrade | Perform | Outperform |
| Aug 7, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 7, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 15, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
